search
Back to results

Postprandial Monocyte Study (PPMS)

Primary Purpose

Immune System, Nutrition, Inflammation

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
High saturated fat challenge meal
High mono unsaturated fat challenge meal
Sponsored by
USDA, Western Human Nutrition Research Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Immune System focused on measuring monocyte, postprandial, nonclassical monocytes

Eligibility Criteria

18 Years - 39 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: BMI 18.5 - 29.9 kg/m² have a bank account and social security number or taxpayer identification for financial compensation Exclusion Criteria: Pregnant or lactating women Known allergy or hindering intolerance to study meal ingredients Systolic blood pressure greater than 140 mmHg or diastolic blood pressure greater than 90 mmHg measured Fasting glucose above 105 mg/dL Triglycerides above 150 mg/dL HDL cholesterol less than 40 mg/dL (men) and 50 mg/dL (women) Self-reported history of difficulties with blood drawing procedures including prior fainting or dizziness, or veins assessed as not suitable for four separate venipunctures by licensed phlebotomist Diagnosed active chronic diseases for which the individual is currently taking daily medication, including but not limited to Diabetes mellitus, Cardiovascular disease, Cancer, Gastrointestinal disorders, Kidney disease, Liver disease, Bleeding disorders, Asthma, Autoimmune disorders, Hypertension, Osteoporosis Recent minor surgery (within 4 wk) or major surgery (within 16 wk) History of gastrointestinal surgery, including gastric bypass surgery or resection Recent antibiotic therapy (within 4 wk) Known gallbladder disease or history of cholecystectomy Recent hospitalization (within 4 wk) Use of prescription medications at the time of the study that directly affect endpoints of interest (e.g. hyperlipidemia, glycemic control, steroids, statins, anti-inflammatory agents, and over-the-counter weight loss aids) Current participation in another research study Less than 18 and over 39 years old BMI less than 18.5 and above 29.9 kg/m² Has HIV/AIDS or another disease that affects the immune system Unable to fast for 12 hours Gives regular blood donations and is unwilling to stop during the study Has monocytosis (>0.8 x 10³/microliter) or other abnormalities in hematologic parameters based on a screening complete blood count (CBC) with differential

Sites / Locations

  • USDA Western Human Nutrition Research CenterRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

High saturated fat challenge meal followed by high mono-unsaturated fat challenge meal

High mono-unsaturated fat challenge meal followed by high saturated fat challenge meal

Arm Description

High saturated fat mixed macronutrient challenge meal with palm oil followed by high mono-unsaturated fat mixed macronutrient challenge meal with olive oil two weeks later

High mono-unsaturated fat mixed macronutrient challenge meal with olive oil followed by high saturated fat mixed macronutrient challenge meal with palm oil two weeks later

Outcomes

Primary Outcome Measures

Change in Monocyte subsets
Monocyte subsets will be analyzed using flow cytometry. Subset analysis will be performed by labeling immune cells with anti-cluster of differentiation antigen 45 (anti-CD45), cluster of differentiation antigen 91 (anti-CD91), anti-CD14, and anti-CD16 fluorescently labeled antibodies.

Secondary Outcome Measures

Change in white blood cell count
White blood cell (WBC) count will be measured by a DxH 520 Hematology analyzer.
Change in lymphocyte count
Lymphocyte (LY) count will be measured by a DxH 520 Hematology analyzer.
Change in monocyte count
Monocyte (MO) count will be measured by a DxH 520 Hematology analyzer.
Change in change in neutrophil granulocyte count
Neutrophil granulocyte (NE) count will be measured by a DxH 520 Hematology analyzer.
Change in eosinophil count
Eosinophil (EO) count will be measured by a DxH 520 Hematology analyzer.
Change in basophil count
Basophil (BA) count will be measured by a DxH 520 Hematology analyzer.
Change in red blood cell count
Red blood cell (RBC) count will be measured by a DxH 520 Hematology analyzer.
Change in hemoglobin
Hemoglobin (HGB) will be measured by a DxH 520 Hematology analyzer.
Change in hematocrit
Hematocrit (HCT) will be measured by a DxH 520 Hematology analyzer.
Change in mean corpuscular volume
Mean corpuscular volume (MCV) will be measured by a DxH 520 Hematology analyzer.
Change in mean corpuscular hemoglobin
Mean corpuscular hemoglobin (MCH) will be measured by a DxH 520 Hematology analyzer.
Change in mean corpuscular hemoglobin concentration
Mean corpuscular hemoglobin concentration (MCHC) will be measured by a DxH 520 Hematology analyzer.
Change in red blood cell distribution width
Red blood cell distribution width (RDW) will be measured by a DxH 520 Hematology analyzer.
Change in red blood cell distribution width standard deviation
Red blood cell distribution width standard deviation (RDW-SD) will be measured by a DxH 520 Hematology analyzer.
Change in platelet count
Platelet (PLT) count will be measured by a DxH 520 Hematology analyzer.
Change in mean platelet volume
Mean platelet volume (MPV) will be measured by a DxH 520 Hematology analyzer.
Change in CD45 gene expression
Transcriptional changes in non-classical and classical monocytes will be measured by RNA-sequencing following the isolation of non-classical monocytes from peripheral blood by fluorescence-activated cell sorting (FACS) using anti-CD45 fluorescently labeled antibodies.
Change in CD91 gene expression
Transcriptional changes in non-classical and classical monocytes will be measured by RNA-sequencing following the isolation of non-classical monocytes from peripheral blood by fluorescence-activated cell sorting (FACS) using anti-CD91 fluorescently labeled antibodies.
Change in CD14 gene expression
Transcriptional changes in non-classical and classical monocytes will be measured by RNA-sequencing following the isolation of non-classical monocytes from peripheral blood by fluorescence-activated cell sorting (FACS) using anti-CD14 fluorescently labeled antibodies.
Change in CD16 gene expression
Transcriptional changes in non-classical and classical monocytes will be measured by RNA-sequencing following the isolation of non-classical monocytes from peripheral blood by fluorescence-activated cell sorting (FACS) using anti-CD16 fluorescently labeled antibodies.
Change in expression of very late antigen-4
Monocyte adhesion molecule expression of very late antigen-4 (VLA-4) will be assessed using flow cytometry.
Change in expression of C-X3-C motif chemokine receptor 1
Monocyte adhesion molecule expression of C-X3-C motif chemokine receptor 1 (CX3CR1) will be assessed using flow cytometry.
Change in expression of Notch2
Monocyte adhesion molecule expression of Notch2 will be assessed using flow cytometry.
Change in expression of colony stimulating factor 1 receptor
Monocyte adhesion molecule expression of colony stimulating factor 1 receptor (CSFR1) will be assessed using flow cytometry.
Change in expression of scavenger receptor class B, member 3
Monocyte adhesion molecule expression of scavenger receptor class B, member 3 (CD36) will be assessed using flow cytometry.
Change in intensity of filamentous-actin
Filamentous-actin (F-actin) intensity will be assessed using phalloidin.
Change in levels of interleukin-6
Plasma markers of systemic inflammation including interleukin-6 will be measured by ELISA.
Change in levels of interleukin-8
Plasma markers of systemic inflammation including interleukin-8 will be measured by ELISA.
Change in levels of C-reactive protein
Acute phase reactants including C-reactive protein (CRP) will be measured by ELISA.
Change in levels of serum amyloid A
Acute phase reactants including serum amyloid A (SAA) will be measured by ELISA.
Change in levels of chemokine ligand 2
Chemokines including chemokine ligand 2 will be measured by ELISA.
Change in levels of 8-isoprostane F2alpha
Plasma markers of oxidative stress including 8-isoprostane F2alpha will be measured by ELISA.
Change in soluble cluster of differentiation antigen 146
Endothelial activation including soluble cluster of differentiation antigen 146 (CD146) will be measured by ELISA.
Change in levels of triglycerides
Lipid-related markers including triglycerides will be measured by auto-analyzer, Cobas Integra 400+ instrument
Change in levels of total cholesterol
Lipid-related markers including total cholesterol will be measured by auto-analyzer, Cobas Integra 400+ instrument
Change in levels of HDL-cholesterol
Lipid-related markers including HDL-cholesterol (HDL-C) will be measured by auto-analyzer, Cobas Integra 400+ instrument
Change in levels of LDL-cholesterol
Lipid-related markers including LDL-cholesterol (LDL-C) will be measured by auto-analyzer, Cobas Integra 400+ instrument
Change in levels of glucose
Plasma glucose will be measured by auto-analyzer, Cobas Integra 400+ instrument

Full Information

First Posted
March 15, 2023
Last Updated
October 17, 2023
Sponsor
USDA, Western Human Nutrition Research Center
search

1. Study Identification

Unique Protocol Identification Number
NCT05792137
Brief Title
Postprandial Monocyte Study
Acronym
PPMS
Official Title
Western Human Nutrition Research Center (WHNRC) Postprandial Monocyte Study
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
October 23, 2023 (Anticipated)
Primary Completion Date
January 2025 (Anticipated)
Study Completion Date
January 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
USDA, Western Human Nutrition Research Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this research is to determine the role of a type of immune cell in blood, called a non-classical monocytes (NCMs), following consumption of a high-fat meal. Previous studies have found that monocytes are important for blood vessel health. In this study, two different high-fat meals will be used to study the effect of different types of dietary fat on postprandial NCMs. The investigators will characterize NCMs in both fasting conditions and following consumption of two different high-fat meals, and will evaluate whether the type of fat in a meal affects NCMs in blood.
Detailed Description
Monocytes are a heterogeneous population of circulating blood cells that contribute to tissue integrity as well as to innate and adaptive immune defense. There are three well-characterized subsets based on their relative expression of surface antigens, cluster of differentiation 14 (CD14) and cluster of differentiation 16 (CD16). Monocytes originate from myeloid precursors in the bone marrow and enter the circulation as classical monocytes (CLMs). CLMs represent a transient cell population with a diverse differentiation potential. CLMs comprise 80-90% of the circulating blood monocyte pool and remain in circulation for approximately one day before either migrating into tissue to repopulate the tissue resident macrophage population or maturing into non-classical monocytes (NCMs). NCMs comprise only 5-10% of the circulating blood monocyte pool but have a much longer circulating lifespan of approximately 7 days. NCMs exhibit conflicting functions as anti-inflammatory caretakers of vascular tissue and as contributors to the pathogenesis of disease. Metabolic responses to food consumption influence the risk of cardiometabolic disease. Postprandial glycemia and lipemia modulate vascular health by altering endothelial function and inducing oxidative stress, inflammation, and apoptosis. Consumption of a single high-fat meal increases circulating interleukin 6 (IL-6), enhances expression of monocyte adhesion molecules, reduces flow-mediated dilation, and increases markers of oxidative stress in human subjects. Although NCMs are described as vascular housekeepers with distinct motility and crawling patterns allowing them to actively surveil endothelium and scavenge luminal debris, their role in the postprandial state is currently unknown. To better understand the function of postprandial NCMs following consumption of a single high-fat mixed macronutrient challenge meal, the investigators propose a study following a crossover design in which participants will consume one of two isocaloric high-fat challenge meals spaced two-weeks apart, a high-saturated fat mixed macronutrient challenge meal or a high-monounsaturated fat mixed macronutrient challenge meal. Blood at fasting and at six hours postprandial will be collected and the proportion of NCMs and their integrin expression will be analyzed by flow cytometry while changes in global gene expression will be measured by RNA-sequencing.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Immune System, Nutrition, Inflammation
Keywords
monocyte, postprandial, nonclassical monocytes

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
30 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
High saturated fat challenge meal followed by high mono-unsaturated fat challenge meal
Arm Type
Experimental
Arm Description
High saturated fat mixed macronutrient challenge meal with palm oil followed by high mono-unsaturated fat mixed macronutrient challenge meal with olive oil two weeks later
Arm Title
High mono-unsaturated fat challenge meal followed by high saturated fat challenge meal
Arm Type
Experimental
Arm Description
High mono-unsaturated fat mixed macronutrient challenge meal with olive oil followed by high saturated fat mixed macronutrient challenge meal with palm oil two weeks later
Intervention Type
Other
Intervention Name(s)
High saturated fat challenge meal
Intervention Description
High saturated fat challenge meal made with palm oil
Intervention Type
Other
Intervention Name(s)
High mono unsaturated fat challenge meal
Intervention Description
High mono unsaturated fat challenge meal made with olive oil
Primary Outcome Measure Information:
Title
Change in Monocyte subsets
Description
Monocyte subsets will be analyzed using flow cytometry. Subset analysis will be performed by labeling immune cells with anti-cluster of differentiation antigen 45 (anti-CD45), cluster of differentiation antigen 91 (anti-CD91), anti-CD14, and anti-CD16 fluorescently labeled antibodies.
Time Frame
Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Secondary Outcome Measure Information:
Title
Change in white blood cell count
Description
White blood cell (WBC) count will be measured by a DxH 520 Hematology analyzer.
Time Frame
Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Title
Change in lymphocyte count
Description
Lymphocyte (LY) count will be measured by a DxH 520 Hematology analyzer.
Time Frame
Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Title
Change in monocyte count
Description
Monocyte (MO) count will be measured by a DxH 520 Hematology analyzer.
Time Frame
Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Title
Change in change in neutrophil granulocyte count
Description
Neutrophil granulocyte (NE) count will be measured by a DxH 520 Hematology analyzer.
Time Frame
Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Title
Change in eosinophil count
Description
Eosinophil (EO) count will be measured by a DxH 520 Hematology analyzer.
Time Frame
Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Title
Change in basophil count
Description
Basophil (BA) count will be measured by a DxH 520 Hematology analyzer.
Time Frame
Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Title
Change in red blood cell count
Description
Red blood cell (RBC) count will be measured by a DxH 520 Hematology analyzer.
Time Frame
Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Title
Change in hemoglobin
Description
Hemoglobin (HGB) will be measured by a DxH 520 Hematology analyzer.
Time Frame
Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Title
Change in hematocrit
Description
Hematocrit (HCT) will be measured by a DxH 520 Hematology analyzer.
Time Frame
Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Title
Change in mean corpuscular volume
Description
Mean corpuscular volume (MCV) will be measured by a DxH 520 Hematology analyzer.
Time Frame
Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Title
Change in mean corpuscular hemoglobin
Description
Mean corpuscular hemoglobin (MCH) will be measured by a DxH 520 Hematology analyzer.
Time Frame
Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Title
Change in mean corpuscular hemoglobin concentration
Description
Mean corpuscular hemoglobin concentration (MCHC) will be measured by a DxH 520 Hematology analyzer.
Time Frame
Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Title
Change in red blood cell distribution width
Description
Red blood cell distribution width (RDW) will be measured by a DxH 520 Hematology analyzer.
Time Frame
Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Title
Change in red blood cell distribution width standard deviation
Description
Red blood cell distribution width standard deviation (RDW-SD) will be measured by a DxH 520 Hematology analyzer.
Time Frame
Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Title
Change in platelet count
Description
Platelet (PLT) count will be measured by a DxH 520 Hematology analyzer.
Time Frame
Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Title
Change in mean platelet volume
Description
Mean platelet volume (MPV) will be measured by a DxH 520 Hematology analyzer.
Time Frame
Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Title
Change in CD45 gene expression
Description
Transcriptional changes in non-classical and classical monocytes will be measured by RNA-sequencing following the isolation of non-classical monocytes from peripheral blood by fluorescence-activated cell sorting (FACS) using anti-CD45 fluorescently labeled antibodies.
Time Frame
Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Title
Change in CD91 gene expression
Description
Transcriptional changes in non-classical and classical monocytes will be measured by RNA-sequencing following the isolation of non-classical monocytes from peripheral blood by fluorescence-activated cell sorting (FACS) using anti-CD91 fluorescently labeled antibodies.
Time Frame
Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Title
Change in CD14 gene expression
Description
Transcriptional changes in non-classical and classical monocytes will be measured by RNA-sequencing following the isolation of non-classical monocytes from peripheral blood by fluorescence-activated cell sorting (FACS) using anti-CD14 fluorescently labeled antibodies.
Time Frame
Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Title
Change in CD16 gene expression
Description
Transcriptional changes in non-classical and classical monocytes will be measured by RNA-sequencing following the isolation of non-classical monocytes from peripheral blood by fluorescence-activated cell sorting (FACS) using anti-CD16 fluorescently labeled antibodies.
Time Frame
Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Title
Change in expression of very late antigen-4
Description
Monocyte adhesion molecule expression of very late antigen-4 (VLA-4) will be assessed using flow cytometry.
Time Frame
Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Title
Change in expression of C-X3-C motif chemokine receptor 1
Description
Monocyte adhesion molecule expression of C-X3-C motif chemokine receptor 1 (CX3CR1) will be assessed using flow cytometry.
Time Frame
Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Title
Change in expression of Notch2
Description
Monocyte adhesion molecule expression of Notch2 will be assessed using flow cytometry.
Time Frame
Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Title
Change in expression of colony stimulating factor 1 receptor
Description
Monocyte adhesion molecule expression of colony stimulating factor 1 receptor (CSFR1) will be assessed using flow cytometry.
Time Frame
Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Title
Change in expression of scavenger receptor class B, member 3
Description
Monocyte adhesion molecule expression of scavenger receptor class B, member 3 (CD36) will be assessed using flow cytometry.
Time Frame
Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Title
Change in intensity of filamentous-actin
Description
Filamentous-actin (F-actin) intensity will be assessed using phalloidin.
Time Frame
Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Title
Change in levels of interleukin-6
Description
Plasma markers of systemic inflammation including interleukin-6 will be measured by ELISA.
Time Frame
Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Title
Change in levels of interleukin-8
Description
Plasma markers of systemic inflammation including interleukin-8 will be measured by ELISA.
Time Frame
Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Title
Change in levels of C-reactive protein
Description
Acute phase reactants including C-reactive protein (CRP) will be measured by ELISA.
Time Frame
Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Title
Change in levels of serum amyloid A
Description
Acute phase reactants including serum amyloid A (SAA) will be measured by ELISA.
Time Frame
Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Title
Change in levels of chemokine ligand 2
Description
Chemokines including chemokine ligand 2 will be measured by ELISA.
Time Frame
Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Title
Change in levels of 8-isoprostane F2alpha
Description
Plasma markers of oxidative stress including 8-isoprostane F2alpha will be measured by ELISA.
Time Frame
Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Title
Change in soluble cluster of differentiation antigen 146
Description
Endothelial activation including soluble cluster of differentiation antigen 146 (CD146) will be measured by ELISA.
Time Frame
Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Title
Change in levels of triglycerides
Description
Lipid-related markers including triglycerides will be measured by auto-analyzer, Cobas Integra 400+ instrument
Time Frame
Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Title
Change in levels of total cholesterol
Description
Lipid-related markers including total cholesterol will be measured by auto-analyzer, Cobas Integra 400+ instrument
Time Frame
Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Title
Change in levels of HDL-cholesterol
Description
Lipid-related markers including HDL-cholesterol (HDL-C) will be measured by auto-analyzer, Cobas Integra 400+ instrument
Time Frame
Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Title
Change in levels of LDL-cholesterol
Description
Lipid-related markers including LDL-cholesterol (LDL-C) will be measured by auto-analyzer, Cobas Integra 400+ instrument
Time Frame
Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Title
Change in levels of glucose
Description
Plasma glucose will be measured by auto-analyzer, Cobas Integra 400+ instrument
Time Frame
Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
39 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: BMI 18.5 - 29.9 kg/m² have a bank account and social security number or taxpayer identification for financial compensation Exclusion Criteria: Pregnant or lactating women Known allergy or hindering intolerance to study meal ingredients Systolic blood pressure greater than 140 mmHg or diastolic blood pressure greater than 90 mmHg measured Fasting glucose above 105 mg/dL Triglycerides above 150 mg/dL HDL cholesterol less than 40 mg/dL (men) and 50 mg/dL (women) Self-reported history of difficulties with blood drawing procedures including prior fainting or dizziness, or veins assessed as not suitable for four separate venipunctures by licensed phlebotomist Diagnosed active chronic diseases for which the individual is currently taking daily medication, including but not limited to Diabetes mellitus, Cardiovascular disease, Cancer, Gastrointestinal disorders, Kidney disease, Liver disease, Bleeding disorders, Asthma, Autoimmune disorders, Hypertension, Osteoporosis Recent minor surgery (within 4 wk) or major surgery (within 16 wk) History of gastrointestinal surgery, including gastric bypass surgery or resection Recent antibiotic therapy (within 4 wk) Known gallbladder disease or history of cholecystectomy Recent hospitalization (within 4 wk) Use of prescription medications at the time of the study that directly affect endpoints of interest (e.g. hyperlipidemia, glycemic control, steroids, statins, anti-inflammatory agents, and over-the-counter weight loss aids) Current participation in another research study Less than 18 and over 39 years old BMI less than 18.5 and above 29.9 kg/m² Has HIV/AIDS or another disease that affects the immune system Unable to fast for 12 hours Gives regular blood donations and is unwilling to stop during the study Has monocytosis (>0.8 x 10³/microliter) or other abnormalities in hematologic parameters based on a screening complete blood count (CBC) with differential
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Ryan Snodgrass, PhD
Phone
530-754-4838
Email
ryan.snodgrass@usda.gov
First Name & Middle Initial & Last Name or Official Title & Degree
Ellen Bonnel, PhD
Phone
530-752-4184
Email
elbonnel@ucdavis.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ryan Snodgrass, PhD
Organizational Affiliation
USDA, Western Human Nutrition Research Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
USDA Western Human Nutrition Research Center
City
Davis
State/Province
California
ZIP/Postal Code
95616
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Charles Stephensen, PhD
Phone
530-304-3528
Email
charles.stephensen@usda.gov

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Postprandial Monocyte Study

We'll reach out to this number within 24 hrs